Cantor Fitzgerald analyst Alethia Young maintained a Hold rating on Regeneron (REGN) today and set a price target of $441. The company’s shares opened today at $410.
Young said:
“: $441 price target. Dermira (OW, Chen) reported positive Ph2b data this morning for IL-13 mAb lebrikizumab (Lebri) in moderate-to-severe atopic dermatitis (AD), where Regeneron’s Dupixent is already approved. We are not surprised by efficacy since the IL-13/IL-4 class has already been validated, although we note high placebo rates. We also think Dupi has the advantage of efficacy in multiple allergic diseases while lebri failed in its Ph3 asthma study in 2016 prompting Roche (NC) to give rights to Dermira. We think that Dupi can maintain leadership position, but are watching competitive readouts in 2019 including ANAB’s (OW, Merle) etokimab and PFE’s (OW, Chen) JAK1.”
According to TipRanks.com, Young is a 5-star analyst with an average return of 9.3% and a 52.9% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $429.38 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $442 and a one-year low of $281.89. Currently, Regeneron has an average volume of 736.6K.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
